EMERGING PUBLIC BIOTECH

HARROW INC (HROW)

Nashville, United States · North America
EMERGING PUBLIC BIOTECH
HEADQUARTERS
Nashville, United States
TICKER
HROW
SEGMENT
Emerging Public Biotech
THERAPY AREAS
KEY PRODUCTS
PRODUCTDETAILS
ImprimisRx
IHEEZO
COMPANY OVERVIEW

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myo…

HARROW INC — FULL INTELLIGENCE

Live regulatory signals, patent cliffs, financials, tariff exposure and pipeline — all free on PharmaSignal.

OPEN PLATFORM →